2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery
Journal of Medicinal Chemistry · 24.08.2023 · 66 (16) · 11027-11039
DOI: 10.1021/acs.jmedchem.3c01178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.08.2023. Verfasst von Aaron M Bender und 4 weiteren Autor:innen. Beteiligte Einrichtung: Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States. Hauptthemen laut MEDLINE: Receptor, Serotonin, 5-HT2B, Heart Valve Diseases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
The cardiotoxicity associated with des-ethyl-dexfenfluramine (norDF) and related agonists of the serotonin receptor 2B (5-HT2B) has solidified the receptor's place as an "antitarget" in drug discovery. Conversely, a growing body of evidence has highlighted the utility of 5-HT2B antagonists for the treatment of pulmonary arterial hypertension (PAH), valvular heart disease (VHD), and related cardiopathies. In this Perspective, we summarize the link between the clinical failure of fenfluramine-phentermine (fen-phen) and the subsequent research on the role of 5-HT2B in disease progression, as well as the development of drug-like and receptor subtype-selective 5-HT2B antagonists. Such agents represent a promising class for the treatment of PAH and VHD, but their utility has been historically understudied due to the clinical disasters associated with 5-HT2B. Herein, it is our aim to examine the current state of 5-HT2B drug discovery, with an emphasis on the receptor's role in the central nervous system (CNS) versus the periphery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
- Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
- Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37240, United States.
- Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
- Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States.
- Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
ORCID-Profile: Aaron M Bender, William B Livingston, Craig W Lindsley
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- NICHD NIH HHS
- Vanderbilt University
- National Cancer Institute
- Vanderbilt Institute of Chemical Biology, School of Medicine, Vanderbilt University
- National Institutes of Health
Zitieren
APA
Bender, A. M., Parr, L. C., Livingston, W. B., Lindsley, C. W., & Merryman, W. D. (2023). 2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery. Journal of Medicinal Chemistry, 66(16), 11027-11039. https://doi.org/10.1021/acs.jmedchem.3c01178
Vancouver
Bender AM, Parr LC, Livingston WB, Lindsley CW, Merryman WD. 2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery. Journal of Medicinal Chemistry. 2023;66(16):11027-11039. doi:10.1021/acs.jmedchem.3c01178
BibTeX
@article{Bender2023,
author = {Bender, Aaron M and Parr, Lauren C and Livingston, William B and Lindsley, Craig W and Merryman, W David},
title = {2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {16},
pages = {11027--11039},
doi = {10.1021/acs.jmedchem.3c01178}
}
EUVIMED